User profiles for "author:Anne M Mills"

Anne M Mills

University of Virginia Department of Pathology
Verified email at virginia.edu
Cited by 2880

Endometrial hyperplasia

KL Ring, AM Mills, SC Modesitt - Obstetrics & Gynecology, 2022 - journals.lww.com
The objectives of this Clinical Expert Series on endometrial hyperplasia are to review the
etiology and risk factors, histologic classification and subtypes, malignant progression risks …

Lynch syndrome screening in the gynecologic tract: current state of the art

AM Mills, TA Longacre - The American journal of surgical …, 2016 - journals.lww.com
Lynch syndrome underlies approximately 5% of endometrial cancers and∼ 1% of ovarian
cancers. Gynecologic malignancies are often the presenting cancer in these patients …

Endometrial hyperplasia

AM Mills, TA Longacre - Seminars in Diagnostic Pathology, 2010 - Elsevier
Endometrial hyperplasia is a heterogeneous set of pathologic lesions that range from mild,
reversible glandular proliferations to direct cancer precursors. These lesions comprise a …

[HTML][HTML] Whole slide imaging versus microscopy for primary diagnosis in surgical pathology: a multicenter blinded randomized noninferiority study of 1992 cases …

S Mukhopadhyay, MD Feldman, E Abels… - The American journal …, 2018 - journals.lww.com
Most prior studies of primary diagnosis in surgical pathology using whole slide imaging
(WSI) versus microscopy have focused on specific organ systems or included relatively few …

Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer

AM Mills, S Liou, JM Ford, JS Berek… - The American journal …, 2014 - journals.lww.com
Lynch syndrome (LS) is an autosomal dominant inherited disorder caused by germline
mutations in DNA mismatch repair (MMR) genes. Mutation carriers are at substantially …

Mismatch repair and microsatellite instability testing for immune checkpoint inhibitor therapy: guideline from the College of American Pathologists in collaboration with …

AN Bartley, AM Mills, E Konnick… - … of pathology & …, 2022 - meridian.allenpress.com
Context.—The US Food and Drug Administration (FDA) approved immune checkpoint
inhibitor therapy for patients with advanced solid tumors that have DNA mismatch repair …

PD-L1 expression and intratumoral heterogeneity across breast cancer subtypes and stages: an assessment of 245 primary and 40 metastatic tumors

EA Dill, AA Gru, KA Atkins, LA Friedman… - The American journal …, 2017 - journals.lww.com
Tumor expression of programmed cell death ligand 1 (PD-L1) is associated with immune
evasion in a variety of malignancies, including a subset of triple-negative breast carcinomas …

Clinically relevant molecular subtypes in leiomyosarcoma

X Guo, VY Jo, AM Mills, SX Zhu, CH Lee, I Espinosa… - Clinical cancer …, 2015 - AACR
Purpose: Leiomyosarcoma is a malignant neoplasm with smooth muscle differentiation.
Little is known about its molecular heterogeneity and no targeted therapy currently exists for …

PD-L1 expression in mismatch repair-deficient endometrial carcinomas, including lynch syndrome-associated and MLH1 promoter hypermethylated tumors

EA Sloan, KL Ring, BC Willis… - The American journal …, 2017 - journals.lww.com
Mismatch repair (MMR)-deficient endometrial carcinomas (ECs) bearing Lynch syndrome
(LS)-associated germline mutations or sporadic MLH1 promoter hypermethylation …

HR-HPV E6/E7 mRNA in situ hybridization: validation against PCR, DNA in situ hybridization, and p16 immunohistochemistry in 102 samples of cervical, vulvar, anal …

AM Mills, DC Dirks, MD Poulter, SE Mills… - The American journal …, 2017 - journals.lww.com
Dysregulated expression of oncogenic types of E6 and E7 is necessary for human
papillomavirus (HPV)-driven carcinogenesis. An HPV E6/E7 mRNA in situ hybridization …